Virvio is a pre-clinical biotherapeutic discovery company and world leader in computationally designed protein scaffolds called "mini-binders" 

Our platform generates mini-binder leads having antibody-like affinity and specificity yet also possessing the hyper-stability and manufacturability of small-molecule drugs. Mini-binders are small structured proteins designed completely de novo to meet the requirements of the molecular target and indication.  

We specialize in addressing difficult molecular targets that traditional antibody or small molecule platforms struggle with and in recapitulation of known antibody functionality for improved administration, dosing, and patent protection.